incrementalnew treatment
JAK inhibitors show early promise in refractory AOSD
Adult-Onset Still's Disease →Summary
Pilot studies and case series of JAK1/2 inhibitors (baricitinib, tofacitinib) in patients with biologic-refractory AOSD demonstrated clinical improvement. JAK inhibition targets downstream signaling of multiple cytokines (IL-6, IFN-gamma, IL-12) simultaneously, offering a potential option when single-cytokine blockade fails.
More from Adult-Onset Still's Disease
significantnew treatment
Anakinra confirmed superior to DMARDs in systemic AOSD: ANAKINRA-STILLS trial
landmarkDiagnostic advance
2023 ACR/EULAR classification criteria for Still's disease published
significantMechanism
Gasdermin D and pyroptosis established as central to AOSD cytokine storm
incrementalMechanism
Neutrophil extracellular traps (NETs) identified in AOSD pathogenesis
ID: adult-onset-stills-disease-update-3Type: new_treatmentImpact: incremental